Q-omics provides the consensus-scored PLPPR5 profile across patient tissues and cancer cell-line models. PLPPR5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PLPPR5 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, PLPPR5 RNA expression shows 11,559 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where PLPPR5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLPPR5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLPPR5 survival associations across molecular data types. PLPPR5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLPPR5 RNA expression–survival associations across cancer types. High PLPPR5 expression shows unfavorable associations in ACC, UVM, SCLC and THCA, but favorable associations in KIRC and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PLPPR5 RNA expression.
This table summarizes PLPPR5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PLPPR5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLPPR5 shows lower tumor expression in LUAD and STAD and higher tumor expression in HNSC, KIRC, KIRP and BRCA. The HNSC box plot shows higher PLPPR5 RNA expression in tumor versus normal tissue (log2 FC = +0.261, t-test p < 0.001).
This table shows molecular features associated with PLPPR5 in patient tissues and cancer cell lines. In patient samples, PLPPR5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PLPPR5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
